{"protocolSection": {"identificationModule": {"nctId": "NCT02570425", "orgStudyIdInfo": {"id": "OR00114"}, "organization": {"fullName": "Research in Real-Life Ltd", "class": "NETWORK"}, "briefTitle": "Comparing Maintenance of Device Mastery With Turbohaler\u00a9 vs. Spiromax\u00a9 in Healthcare Professionals na\u00efve to Both Devices", "officialTitle": "THE HCP ELIOT STUDY: Comparing Maintenance of Device Mastery With TURBOHALER\u00a9 vs. SPIROMAX\u00a9 in Healthcare Professionals na\u00efve to Both Devices (The Easy Low Instruction Over Time [ELIOT] Study)", "acronym": "HCP-ELIOT"}, "statusModule": {"statusVerifiedDate": "2016-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-07"}, "primaryCompletionDateStruct": {"date": "2014-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-08-07", "studyFirstSubmitQcDate": "2015-10-05", "studyFirstPostDateStruct": {"date": "2015-10-07", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-10-13", "resultsFirstSubmitQcDate": "2016-04-27", "resultsFirstPostDateStruct": {"date": "2016-05-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-04-27", "lastUpdatePostDateStruct": {"date": "2016-05-30", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Research in Real-Life Ltd", "class": "NETWORK"}, "collaborators": [{"name": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}, {"name": "University of Sydney", "class": "OTHER"}, {"name": "Woolcock Institute of Medical Research", "class": "OTHER"}, {"name": "University of Technology, Sydney", "class": "OTHER"}, {"name": "The University of New South Wales", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This study is conducted to assess the ease of device mastery of a placebo SYMBICORT TURBOHALER vs a placebo Budesonide/Formoterol SPIROMAX device among healthcare professionals in-training (HCP).", "detailedDescription": "The purpose of this study is to identify how intuitive devices are to use and what level of training is required to ensure that HCPs are able to demonstrate the correct technique. The two devices examined will be the SYMBICORT TURBOHALER and placebo Budesonide/Formoterol SPIROMAX device among healthcare professionals (HCP)."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 516, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Spiromax followed by Turbohaler", "type": "PLACEBO_COMPARATOR", "description": "Training on BF Spiromax followed by SYMBICORT Turbohaler", "interventionNames": ["Device: Training on BF Spiromax followed by SYMBICORT Turbohaler", "Device: Training on SYMBICORT Turbohaler followed by BF Spiromax"]}, {"label": "Turbohaler followed by Spiromax", "type": "PLACEBO_COMPARATOR", "description": "Training on SYMBICORT Turbohaler followed by BF Spiromax", "interventionNames": ["Device: Training on BF Spiromax followed by SYMBICORT Turbohaler", "Device: Training on SYMBICORT Turbohaler followed by BF Spiromax"]}], "interventions": [{"type": "DEVICE", "name": "Training on BF Spiromax followed by SYMBICORT Turbohaler", "description": "Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.", "armGroupLabels": ["Spiromax followed by Turbohaler", "Turbohaler followed by Spiromax"]}, {"type": "DEVICE", "name": "Training on SYMBICORT Turbohaler followed by BF Spiromax", "description": "Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.", "armGroupLabels": ["Spiromax followed by Turbohaler", "Turbohaler followed by Spiromax"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Participants Maintaining Correct Inhaler Technique for Spiromax Compared With Turbohaler 4 Weeks After Training as Assessed by Expert Assessor", "description": "Examine if recall of device mastery is superior for the SPIROMAX inhaler as compared to the TURBOHALER after training to device mastery on both devices.\n\nThe proportion of subjects achieving mastery of inhaler technique between the two inhaler devices was compared using McNemar's test of equality of paired proportions with a 0.050 two- sided significance level. A Conditional Logistic Regression Model was used to quantify the difference between the two inhalers by calculating the odds ratio for achieving mastery for Spiromax\u00ae (with Turbohaler\u00ae as the reference device) along with a 95% confidence interval for quantifying the precision of the odds ratio estimate.", "timeFrame": "4 weeks"}], "secondaryOutcomes": [{"measure": "Percentage of Participants Achieving Device Mastery at the End of Level 1 Out of a 6 Level Training Process as Assessed by Expert Assessor", "description": "Examined for both at the end of level 1 (out of 6 level training process). This will be compared using McNemar's test of equality of paired proportions with a 0.050 two- sided significance level. A Conditional Logistic Regression Model was used to quantify the difference between the two inhalers by calculating the odds ratio for achieving mastery for Spiromax\u00ae (with Turbohaler\u00ae as the reference device) along with a 95% confidence interval for quantifying the precision of the odds ratio estimate.", "timeFrame": "0 weeks (Visit 1)"}, {"measure": "Percentage of Participants Achieving Device Mastery at the End of Level 2 Out of a 6 Level Training Process as Assessed by Expert Assessor", "description": "Examined for both at the end of level 2 (out of 6 level training process). This will be compared using McNemar's test of equality of paired proportions with a 0.050 two- sided significance level. A Conditional Logistic Regression Model was used to quantify the difference between the two inhalers by calculating the odds ratio for achieving mastery for Spiromax\u00ae (with Turbohaler\u00ae as the reference device) along with a 95% confidence interval for quantifying the precision of the odds ratio estimate.", "timeFrame": "0 weeks (Visit 1)"}, {"measure": "Percentage of Participants Achieving Device Mastery at the End of Level 1 Out of a 6 Level Training Process at Week 4 as Assessed by Expert Assessor", "description": "Examined at the end of level 1 (out of 6 level training process). This will be compared using McNemar's test of equality of paired proportions with a 0.050 two- sided significance level. A Conditional Logistic Regression Model was used to quantify the difference between the two inhalers by calculating the odds ratio for achieving mastery for Spiromax\u00ae (with Turbohaler\u00ae as the reference device) along with a 95% confidence interval for quantifying the precision of the odds ratio estimate.", "timeFrame": "4 weeks"}, {"measure": "Percentage of Participants Achieving Device Mastery at the End of Level 2 Out of a 6 Level Training Process at Week 4 as Assessed by Expert Assessor", "description": "Examined at the end of level 2 (out of 6 level training process). This will be compared using McNemar's test of equality of paired proportions with a 0.050 two- sided significance level. A Conditional Logistic Regression Model was used to quantify the difference between the two inhalers by calculating the odds ratio for achieving mastery for Spiromax\u00ae (with Turbohaler\u00ae as the reference device) along with a 95% confidence interval for quantifying the precision of the odds ratio estimate.", "timeFrame": "4 weeks"}, {"measure": "Percentage of Participants Achieving Device Mastery at the End of Level 1 Out of a 6 Level Training Process at Week 8 as Assessed by Expert Assessor", "description": "Examined for both at the end of level 1 (out of 6 level training process). This will be compared using McNemar's test of equality of paired proportions with a 0.050 two- sided significance level. A Conditional Logistic Regression Model was used to quantify the difference between the two inhalers by calculating the odds ratio for achieving mastery for Spiromax\u00ae (with Turbohaler\u00ae as the reference device) along with a 95% confidence interval for quantifying the precision of the odds ratio estimate.", "timeFrame": "8 weeks"}, {"measure": "Percentage of Participants Achieving Device Mastery at the End of Level 2 Out of a 6 Level Training Process at Week 8 as Assessed by Expert Assessor", "description": "Examined for both at the end of level 2 (out of 6 level training process). This will be compared using McNemar's test of equality of paired proportions with a 0.050 two- sided significance level. A Conditional Logistic Regression Model was used to quantify the difference between the two inhalers by calculating the odds ratio for achieving mastery for Spiromax\u00ae (with Turbohaler\u00ae as the reference device) along with a 95% confidence interval for quantifying the precision of the odds ratio estimate.", "timeFrame": "8 weeks"}, {"measure": "Number of Participants Achieving Device Mastery at Levels 1-6 as Assessed by Expert Assessor", "description": "Number of participants achieving mastery at each level in the 6 level training process at baseline visit as assessed by expert assessor", "timeFrame": "0 weeks (Visit 1)"}, {"measure": "Number of Participants Achieving Device Masteryin Levels 1-6 After 4 Weeks From Baseline Visit as Assessed by Expert Assessor", "description": "Number of participants achieving mastery at each level in the 6 level training process after 4 weeks from baseline visit as assessed by expert assessor", "timeFrame": "0 weeks (Visit 1)"}, {"measure": "Number of Participants Achieving Device Mastery in Levels 1-6 After 8 Weeks From Baseline Visit as Assessed by Expert Assessor", "description": "Number of participants achieving mastery at each level in the 6 level training process after 8 weeks from baseline visit as assessed by expert assessor", "timeFrame": "8 weeks"}, {"measure": "The Number of Levels Out of a 6 Level Training Process Required by Each Patient on Achieving Device Mastery as Assessed by Expert Assessor", "description": "Number of levels required to achieve device mastery out of a 6 level training processrequired by each patient at each visit as assessed by expert assessor", "timeFrame": "4 weeks"}, {"measure": "Number of Assessor-observed Errors Recalled During Baseline Visit by All Participants", "description": "Quantity of errors made at each level recalled during baseline visit by all participants using an expert assessor", "timeFrame": "0 weeks (Visit 1)"}, {"measure": "Number of Assessor-observed Errors Recalled at 4 Weeks After Baseline Visit by All Participants", "description": "Quantity of errors made at each level recalled by expert assessors at 4 weeks after baseline visit by all participants", "timeFrame": "4 weeks"}, {"measure": "Number of Assessor-observed Errors Recalled 8 Weeks After Baseline Visit by All Participants", "description": "Quantity of errors made at each level recalled by expert assessors at 8 weeks after baseline visit by all participants", "timeFrame": "8 weeks"}, {"measure": "Type of Participant Handling Errors Recalled by Expert Assessors at Baseline Visit by All Participants", "timeFrame": "0 weeks (Visit 1)"}, {"measure": "Type of Participant Handling Errors by Expert Assessors 4 Weeks After Baseline Visit by All Participants", "timeFrame": "4 weeks"}, {"measure": "Type of Participant Handling Errors Recalled by Expert Assessors 8 Weeks After Baseline Visit by All Participants", "timeFrame": "8 weeks"}, {"measure": "Preference of Participant Device Questionnaire Assessed by PASAPQ Part II Q15 Score", "description": "Device preference for either Spiromax or Turbohaler device at baseline assessed by PASAPQ Part II Q15 score", "timeFrame": "0 weeks (Visit 1)"}, {"measure": "Preference of Device Questionnaire 4 Weeks After Baseline Visit Assessed by PASAPQ Part II Q15 Score", "description": "Device preference for either Spiromax or Turbohaler device 4 weeks after baseline visit assessed by PASAPQ Part II Q15 score", "timeFrame": "4 weeks"}, {"measure": "Preference of Device Questionnaire 8 Weeks After Baseline Visit Assessed by PASAPQ Part II Q15 Score", "description": "Device preference for either Spiromax or Turbohaler device 8 weeks after baseline visit assessed by PASAPQ Part II Q15 score", "timeFrame": "8 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent is obtained and dated by the participant before conducting any study related procedures.\n* The participant is a student that is currently enrolled in the University where the study is conducted\n* The participant must be willing and able to comply with study restrictions and to remain at the study site for the required duration during the study period, and willing to return to the site for the follow up evaluation as specified in this protocol.\n* The participant has not previously used or received training in the use of either the SPIROMAX or the TURBOHALER in the last 6 months\n\nExclusion Criteria:\n\n* Participants will be excluded from participating in this study if they have asthma.", "healthyVolunteers": true, "sex": "ALL", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Sinthia Bosnic-Anticevich, PhD", "affiliation": "University of Sydney", "role": "PRINCIPAL_INVESTIGATOR"}]}, "referencesModule": {"references": [{"pmid": "23510684", "type": "BACKGROUND", "citation": "Al-Jahdali H, Ahmed A, Al-Harbi A, Khan M, Baharoon S, Bin Salih S, Halwani R, Al-Muhsen S. Improper inhaler technique is associated with poor asthma control and frequent emergency department visits. Allergy Asthma Clin Immunol. 2013 Mar 6;9(1):8. doi: 10.1186/1710-1492-9-8."}, {"pmid": "19513170", "type": "BACKGROUND", "citation": "Basheti IA, Armour CL, Reddel HK, Bosnic-Anticevich SZ. Long-term maintenance of pharmacists' inhaler technique demonstration skills. Am J Pharm Educ. 2009 Apr 7;73(2):32. doi: 10.5688/aj730232."}, {"pmid": "18314294", "type": "BACKGROUND", "citation": "Basheti IA, Armour CL, Bosnic-Anticevich SZ, Reddel HK. Evaluation of a novel educational strategy, including inhaler-based reminder labels, to improve asthma inhaler technique. Patient Educ Couns. 2008 Jul;72(1):26-33. doi: 10.1016/j.pec.2008.01.014. Epub 2008 Mar 7."}, {"pmid": "10669525", "type": "BACKGROUND", "citation": "Beasley R, Crane J, Lai CK, Pearce N. Prevalence and etiology of asthma. J Allergy Clin Immunol. 2000 Feb;105(2 Pt 2):S466-72. doi: 10.1016/s0091-6749(00)90044-7."}, {"pmid": "11742268", "type": "BACKGROUND", "citation": "Cain WT, Cable G, Oppenheimer JJ. The ability of the community pharmacist to learn the proper actuation techniques of inhaler devices. J Allergy Clin Immunol. 2001 Dec;108(6):918-20. doi: 10.1067/mai.2001.119153."}, {"pmid": "17983880", "type": "BACKGROUND", "citation": "National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138. doi: 10.1016/j.jaci.2007.09.043. Erratum In: J Allergy Clin Immunol. 2008 Jun;121(6):1330."}, {"pmid": "11866004", "type": "BACKGROUND", "citation": "Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J. 2002 Feb;19(2):246-51. doi: 10.1183/09031936.02.00218402."}, {"pmid": "15080802", "type": "BACKGROUND", "citation": "Gupta R, Sheikh A, Strachan DP, Anderson HR. Burden of allergic disease in the UK: secondary analyses of national databases. Clin Exp Allergy. 2004 Apr;34(4):520-6. doi: 10.1111/j.1365-2222.2004.1935.x."}, {"pmid": "8275720", "type": "BACKGROUND", "citation": "Hanania NA, Wittman R, Kesten S, Chapman KR. Medical personnel's knowledge of and ability to use inhaling devices. Metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest. 1994 Jan;105(1):111-6. doi: 10.1378/chest.105.1.111."}, {"pmid": "20472415", "type": "BACKGROUND", "citation": "Haughney J, Price D, Barnes NC, Virchow JC, Roche N, Chrystyn H. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med. 2010 Sep;104(9):1237-45. doi: 10.1016/j.rmed.2010.04.012. Epub 2010 May 15."}, {"pmid": "18815019", "type": "BACKGROUND", "citation": "Haughney J, Price D, Kaplan A, Chrystyn H, Horne R, May N, Moffat M, Versnel J, Shanahan ER, Hillyer EV, Tunsater A, Bjermer L. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med. 2008 Dec;102(12):1681-93. doi: 10.1016/j.rmed.2008.08.003. Epub 2008 Sep 23."}, {"pmid": "21623690", "type": "BACKGROUND", "citation": "Ovchinikova L, Smith L, Bosnic-Anticevich S. Inhaler technique maintenance: gaining an understanding from the patient's perspective. J Asthma. 2011 Aug;48(6):616-24. doi: 10.3109/02770903.2011.580032. Epub 2011 May 31."}, {"pmid": "21532013", "type": "BACKGROUND", "citation": "Papi A, Haughney J, Virchow JC, Roche N, Palkonen S, Price D. Inhaler devices for asthma: a call for action in a neglected field. Eur Respir J. 2011 May;37(5):982-5. doi: 10.1183/09031936.00150910. No abstract available."}, {"pmid": "20514388", "type": "BACKGROUND", "citation": "Pinnock H, Thomas M, Tsiligianni I, Lisspers K, Ostrem A, Stallberg B, Yusuf O, Ryan D, Buffels J, Cals JW, Chavannes NH, Henrichsen SH, Langhammer A, Latysheva E, Lionis C, Litt J, van der Molen T, Zwar N, Williams S. The International Primary Care Respiratory Group (IPCRG) Research Needs Statement 2010. Prim Care Respir J. 2010 Jun;19 Suppl 1(Suppl 1):S1-20. doi: 10.4104/pcrj.2010.00021."}, {"pmid": "23098685", "type": "BACKGROUND", "citation": "Inhaler Error Steering Committee; Price D, Bosnic-Anticevich S, Briggs A, Chrystyn H, Rand C, Scheuch G, Bousquet J. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med. 2013 Jan;107(1):37-46. doi: 10.1016/j.rmed.2012.09.017. Epub 2012 Oct 23."}, {"pmid": "29954359", "type": "DERIVED", "citation": "Price DB, Thomas V, Richard Dekhuijzen PN, Bosnic-Anticevich S, Roche N, Lavorini F, Raju P, Freeman D, Nicholls C, Small IR, Sims E, Safioti G, Canvin J, Chrystyn H. Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax(R) compared with budesonide/formoterol Turbuhaler(R) in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study. BMC Pulm Med. 2018 Jun 28;18(1):107. doi: 10.1186/s12890-018-0665-x."}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED", "description": "Decision has not been made"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants were re-randomised to either the BF Spiromax first or Symbicort Turbohaler first at each visit.", "groups": [{"id": "FG000", "title": "Placebo Comparator: Spiromax Followed by Turbohaler", "description": "Training on BF Spiromax followed by SYMBICORT Turbohaler"}, {"id": "FG001", "title": "Placebo Comparator: Turbohaler Followed by Spiromax", "description": "Training on SYMBICORT Turbohaler followed by BF Spiromax"}], "periods": [{"title": "Visit 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "274"}, {"groupId": "FG001", "numSubjects": "242"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "274"}, {"groupId": "FG001", "numSubjects": "242"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Visit 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "In total 18 patients who completed Visit 1, did not attend Visit 2.", "numSubjects": "251"}, {"groupId": "FG001", "comment": "In total 18 patients who completed Visit 1, did not attend Visit 2.", "numSubjects": "247"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "251"}, {"groupId": "FG001", "numSubjects": "247"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Visit 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "In total 38 patients who completed Visit 2, did not attend Visit 3.", "numSubjects": "229"}, {"groupId": "FG001", "comment": "In total 38 patients who completed Visit 2, did not attend Visit 3.", "numSubjects": "231"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "229"}, {"groupId": "FG001", "numSubjects": "231"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "SYMBICORT Turbohaler\u00ae First, Then Spiromax\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device at baseline"}, {"id": "BG001", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae First, Then Turbohaler\u00ae", "description": "Traing HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "242"}, {"groupId": "BG001", "value": "274"}, {"groupId": "BG002", "value": "516"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "242"}, {"groupId": "BG001", "value": "274"}, {"groupId": "BG002", "value": "516"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "22.9", "spread": "4.5"}, {"groupId": "BG001", "value": "22.3", "spread": "4.7"}, {"groupId": "BG002", "value": "22.6", "spread": "4.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "146"}, {"groupId": "BG001", "value": "169"}, {"groupId": "BG002", "value": "315"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "96"}, {"groupId": "BG001", "value": "105"}, {"groupId": "BG002", "value": "201"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Australia", "categories": [{"measurements": [{"groupId": "BG000", "value": "242"}, {"groupId": "BG001", "value": "274"}, {"groupId": "BG002", "value": "516"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Participants Maintaining Correct Inhaler Technique for Spiromax Compared With Turbohaler 4 Weeks After Training as Assessed by Expert Assessor", "description": "Examine if recall of device mastery is superior for the SPIROMAX inhaler as compared to the TURBOHALER after training to device mastery on both devices.\n\nThe proportion of subjects achieving mastery of inhaler technique between the two inhaler devices was compared using McNemar's test of equality of paired proportions with a 0.050 two- sided significance level. A Conditional Logistic Regression Model was used to quantify the difference between the two inhalers by calculating the odds ratio for achieving mastery for Spiromax\u00ae (with Turbohaler\u00ae as the reference device) along with a 95% confidence interval for quantifying the precision of the odds ratio estimate.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device at baseline"}, {"id": "OG001", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Traing HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "498"}, {"groupId": "OG001", "value": "498"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "64"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving Device Mastery at the End of Level 1 Out of a 6 Level Training Process as Assessed by Expert Assessor", "description": "Examined for both at the end of level 1 (out of 6 level training process). This will be compared using McNemar's test of equality of paired proportions with a 0.050 two- sided significance level. A Conditional Logistic Regression Model was used to quantify the difference between the two inhalers by calculating the odds ratio for achieving mastery for Spiromax\u00ae (with Turbohaler\u00ae as the reference device) along with a 95% confidence interval for quantifying the precision of the odds ratio estimate.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "0 weeks (Visit 1)", "groups": [{"id": "OG000", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device at baseline"}, {"id": "OG001", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Traing HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "516"}, {"groupId": "OG001", "value": "516"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "22"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving Device Mastery at the End of Level 2 Out of a 6 Level Training Process as Assessed by Expert Assessor", "description": "Examined for both at the end of level 2 (out of 6 level training process). This will be compared using McNemar's test of equality of paired proportions with a 0.050 two- sided significance level. A Conditional Logistic Regression Model was used to quantify the difference between the two inhalers by calculating the odds ratio for achieving mastery for Spiromax\u00ae (with Turbohaler\u00ae as the reference device) along with a 95% confidence interval for quantifying the precision of the odds ratio estimate.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "0 weeks (Visit 1)", "groups": [{"id": "OG000", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device at baseline"}, {"id": "OG001", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Traing HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "516"}, {"groupId": "OG001", "value": "516"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "58"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving Device Mastery at the End of Level 1 Out of a 6 Level Training Process at Week 4 as Assessed by Expert Assessor", "description": "Examined at the end of level 1 (out of 6 level training process). This will be compared using McNemar's test of equality of paired proportions with a 0.050 two- sided significance level. A Conditional Logistic Regression Model was used to quantify the difference between the two inhalers by calculating the odds ratio for achieving mastery for Spiromax\u00ae (with Turbohaler\u00ae as the reference device) along with a 95% confidence interval for quantifying the precision of the odds ratio estimate.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device at baseline"}, {"id": "OG001", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Traing HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "498"}, {"groupId": "OG001", "value": "498"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "64"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving Device Mastery at the End of Level 2 Out of a 6 Level Training Process at Week 4 as Assessed by Expert Assessor", "description": "Examined at the end of level 2 (out of 6 level training process). This will be compared using McNemar's test of equality of paired proportions with a 0.050 two- sided significance level. A Conditional Logistic Regression Model was used to quantify the difference between the two inhalers by calculating the odds ratio for achieving mastery for Spiromax\u00ae (with Turbohaler\u00ae as the reference device) along with a 95% confidence interval for quantifying the precision of the odds ratio estimate.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device at baseline"}, {"id": "OG001", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Traing HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "498"}, {"groupId": "OG001", "value": "498"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "86"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving Device Mastery at the End of Level 1 Out of a 6 Level Training Process at Week 8 as Assessed by Expert Assessor", "description": "Examined for both at the end of level 1 (out of 6 level training process). This will be compared using McNemar's test of equality of paired proportions with a 0.050 two- sided significance level. A Conditional Logistic Regression Model was used to quantify the difference between the two inhalers by calculating the odds ratio for achieving mastery for Spiromax\u00ae (with Turbohaler\u00ae as the reference device) along with a 95% confidence interval for quantifying the precision of the odds ratio estimate.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device at baseline"}, {"id": "OG001", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Traing HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "460"}, {"groupId": "OG001", "value": "460"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "79"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving Device Mastery at the End of Level 2 Out of a 6 Level Training Process at Week 8 as Assessed by Expert Assessor", "description": "Examined for both at the end of level 2 (out of 6 level training process). This will be compared using McNemar's test of equality of paired proportions with a 0.050 two- sided significance level. A Conditional Logistic Regression Model was used to quantify the difference between the two inhalers by calculating the odds ratio for achieving mastery for Spiromax\u00ae (with Turbohaler\u00ae as the reference device) along with a 95% confidence interval for quantifying the precision of the odds ratio estimate.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device at baseline"}, {"id": "OG001", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Traing HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "460"}, {"groupId": "OG001", "value": "460"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "93"}, {"groupId": "OG001", "value": "92"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Device Mastery at Levels 1-6 as Assessed by Expert Assessor", "description": "Number of participants achieving mastery at each level in the 6 level training process at baseline visit as assessed by expert assessor", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "0 weeks (Visit 1)", "groups": [{"id": "OG000", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device at baseline"}, {"id": "OG001", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Traing HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "516"}, {"groupId": "OG001", "value": "516"}]}], "classes": [{"title": "Level 1: Intuitive Use", "categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "113"}]}]}, {"title": "Level 2: Patient Information Leaflet", "categories": [{"measurements": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "186"}]}]}, {"title": "Level 3: Instructional Video", "categories": [{"measurements": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "87"}]}]}, {"title": "Level 4: Expert Tuition", "categories": [{"measurements": [{"groupId": "OG000", "value": "158"}, {"groupId": "OG001", "value": "116"}]}]}, {"title": "Level 5: Repeat of Expert Tuition", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "13"}]}]}, {"title": "Level 6: Second Repeat of Expert Tuition", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Device Masteryin Levels 1-6 After 4 Weeks From Baseline Visit as Assessed by Expert Assessor", "description": "Number of participants achieving mastery at each level in the 6 level training process after 4 weeks from baseline visit as assessed by expert assessor", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "0 weeks (Visit 1)", "groups": [{"id": "OG000", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device at baseline"}, {"id": "OG001", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Traing HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "498"}, {"groupId": "OG001", "value": "498"}]}], "classes": [{"title": "Level 1: Intuitive Use", "categories": [{"measurements": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "317"}]}]}, {"title": "Level 2: Patient Information Leaflet", "categories": [{"measurements": [{"groupId": "OG000", "value": "182"}, {"groupId": "OG001", "value": "113"}]}]}, {"title": "Level 3: Instructional Video", "categories": [{"measurements": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "34"}]}]}, {"title": "Level 4: Expert Tuition", "categories": [{"measurements": [{"groupId": "OG000", "value": "47"}, {"groupId": "OG001", "value": "31"}]}]}, {"title": "Level 5: Repeat of Expert Tuition", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Level 6: Second Repeat of Expert Tuition", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Achieving Device Mastery in Levels 1-6 After 8 Weeks From Baseline Visit as Assessed by Expert Assessor", "description": "Number of participants achieving mastery at each level in the 6 level training process after 8 weeks from baseline visit as assessed by expert assessor", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device at baseline"}, {"id": "OG001", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Traing HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "460"}, {"groupId": "OG001", "value": "460"}]}], "classes": [{"title": "Level 1: Intuitive Use", "categories": [{"measurements": [{"groupId": "OG000", "value": "299"}, {"groupId": "OG001", "value": "362"}]}]}, {"title": "Level 2: Patient Information Leaflet", "categories": [{"measurements": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "63"}]}]}, {"title": "Level 3: Instructional Video", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "20"}]}]}, {"title": "Level 4: Expert Tuition", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "19"}]}]}, {"title": "Level 5: Repeat of Expert Tuition", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Level 6: Second Repeat of Expert Tuition", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "The Number of Levels Out of a 6 Level Training Process Required by Each Patient on Achieving Device Mastery as Assessed by Expert Assessor", "description": "Number of levels required to achieve device mastery out of a 6 level training processrequired by each patient at each visit as assessed by expert assessor", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "levels", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Training HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}, {"id": "OG001", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "516"}, {"groupId": "OG001", "value": "516"}]}], "classes": [{"title": "Visit 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.48", "spread": "1.15"}, {"groupId": "OG001", "value": "3.03", "spread": "3.0"}]}]}, {"title": "Visit 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.57", "spread": "0.91"}, {"groupId": "OG001", "value": "1.94", "spread": "1.01"}]}]}, {"title": "Visit 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.33", "spread": "0.73"}, {"groupId": "OG001", "value": "1.45", "spread": "0.72"}]}]}]}, {"type": "SECONDARY", "title": "Number of Assessor-observed Errors Recalled During Baseline Visit by All Participants", "description": "Quantity of errors made at each level recalled during baseline visit by all participants using an expert assessor", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "errors", "timeFrame": "0 weeks (Visit 1)", "groups": [{"id": "OG000", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device at baseline"}, {"id": "OG001", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Traing HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "516"}, {"groupId": "OG001", "value": "516"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2540"}, {"groupId": "OG001", "value": "1447"}]}]}]}, {"type": "SECONDARY", "title": "Number of Assessor-observed Errors Recalled at 4 Weeks After Baseline Visit by All Participants", "description": "Quantity of errors made at each level recalled by expert assessors at 4 weeks after baseline visit by all participants", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "errors", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device at baseline"}, {"id": "OG001", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Traing HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "498"}, {"groupId": "OG001", "value": "498"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "780"}, {"groupId": "OG001", "value": "367"}]}]}]}, {"type": "SECONDARY", "title": "Number of Assessor-observed Errors Recalled 8 Weeks After Baseline Visit by All Participants", "description": "Quantity of errors made at each level recalled by expert assessors at 8 weeks after baseline visit by all participants", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "errors", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device at baseline"}, {"id": "OG001", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Traing HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "460"}, {"groupId": "OG001", "value": "460"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "296"}, {"groupId": "OG001", "value": "175"}]}]}]}, {"type": "SECONDARY", "title": "Type of Participant Handling Errors Recalled by Expert Assessors at Baseline Visit by All Participants", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "errors", "timeFrame": "0 weeks (Visit 1)", "groups": [{"id": "OG000", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Training HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}, {"id": "OG001", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "516"}, {"groupId": "OG001", "value": "516"}]}], "classes": [{"title": "Not holding device with mouthpiece cover at bottom", "categories": [{"measurements": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Device is not held upright (\u00b190\u00b0) during dose prep", "categories": [{"measurements": [{"groupId": "OG000", "value": "318"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Device is not held upright (\u00b145\u00b0) during dose prep", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "614"}]}]}, {"title": "Not twisting the base until it clicks", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "557"}]}]}, {"title": "Vigorous shaking before or after dose preparation", "categories": [{"measurements": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "29"}]}]}, {"title": "Exhales into the device before taking a dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "101"}]}]}, {"title": "Inhalation is not as fast as possible from start", "categories": [{"measurements": [{"groupId": "OG000", "value": "613"}, {"groupId": "OG001", "value": "581"}]}]}, {"title": "Does not remove cap", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Inhaler not held upright (\u00b1 45\u00b0) until inhalation", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "402"}]}]}, {"title": "Fails to seal lips around mouthpi", "categories": [{"measurements": [{"groupId": "OG000", "value": "131"}, {"groupId": "OG001", "value": "157"}]}]}, {"title": "Puts fingers or mouth/face around air inlets", "categories": [{"measurements": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "93"}]}]}, {"title": "Does not open cap", "categories": [{"measurements": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "A click is not heard when the cap is opened", "categories": [{"measurements": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Type of Participant Handling Errors by Expert Assessors 4 Weeks After Baseline Visit by All Participants", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "errors", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Training HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}, {"id": "OG001", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "498"}, {"groupId": "OG001", "value": "498"}]}], "classes": [{"title": "Not holding device with mouthpiece cover at bottom", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Device is not held upright (\u00b190\u00b0) during dose prep", "categories": [{"measurements": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Device is not held upright (\u00b145\u00b0) during dose prep", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "184"}]}]}, {"title": "Not twisting the base until it clicks", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "204"}]}]}, {"title": "Vigorous shaking before or after dose preparation", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Exhales into the device before taking a dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "36"}]}]}, {"title": "Inhalation is not as fast as possible from start", "categories": [{"measurements": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "166"}]}]}, {"title": "Does not remove cap", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Inhaler not held upright (\u00b1 45\u00b0) until inhalation", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "119"}]}]}, {"title": "Fails to seal lips around mouthpi", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "20"}]}]}, {"title": "Puts fingers or mouth/face around air inlets", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "43"}]}]}, {"title": "Does not open cap", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "A click is not heard when the cap is opened", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Type of Participant Handling Errors Recalled by Expert Assessors 8 Weeks After Baseline Visit by All Participants", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "errors", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Training HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}, {"id": "OG001", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "460"}, {"groupId": "OG001", "value": "460"}]}], "classes": [{"title": "Not holding device with mouthpiece cover at bottom", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Device is not held upright (\u00b190\u00b0) during dose prep", "categories": [{"measurements": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Device is not held upright (\u00b145\u00b0) during dose prep", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "70"}]}]}, {"title": "Not twisting the base until it clicks", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "49"}]}]}, {"title": "Vigorous shaking before or after dose preparation", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Exhales into the device before taking a dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "19"}]}]}, {"title": "Inhalation is not as fast as possible from start", "categories": [{"measurements": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "82"}]}]}, {"title": "Does not remove cap", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Inhaler not held upright (\u00b1 45\u00b0) until inhalation", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "30"}]}]}, {"title": "Fails to seal lips around mouthpi", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Puts fingers or mouth/face around air inlets", "categories": [{"measurements": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "39"}]}]}, {"title": "Does not open cap", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "A click is not heard when the cap is opened", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Preference of Participant Device Questionnaire Assessed by PASAPQ Part II Q15 Score", "description": "Device preference for either Spiromax or Turbohaler device at baseline assessed by PASAPQ Part II Q15 score", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "0 weeks (Visit 1)", "groups": [{"id": "OG000", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Training HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}, {"id": "OG001", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}, {"id": "OG002", "title": "No Preference", "description": "HCPs indicated no preference of device during training with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device or placebo comparator: SYMBICORT\u00ae Turbohaler using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "516"}, {"groupId": "OG001", "value": "516"}, {"groupId": "OG002", "value": "516"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "10"}]}]}]}, {"type": "SECONDARY", "title": "Preference of Device Questionnaire 4 Weeks After Baseline Visit Assessed by PASAPQ Part II Q15 Score", "description": "Device preference for either Spiromax or Turbohaler device 4 weeks after baseline visit assessed by PASAPQ Part II Q15 score", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Training HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}, {"id": "OG001", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}, {"id": "OG002", "title": "No Preference", "description": "HCPs indicated no preference of device during training with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device or placebo comparator: SYMBICORT\u00ae Turbohaler using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "498"}, {"groupId": "OG001", "value": "498"}, {"groupId": "OG002", "value": "498"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "74.5"}, {"groupId": "OG001", "value": "15.5"}, {"groupId": "OG002", "value": "10"}]}]}]}, {"type": "SECONDARY", "title": "Preference of Device Questionnaire 8 Weeks After Baseline Visit Assessed by PASAPQ Part II Q15 Score", "description": "Device preference for either Spiromax or Turbohaler device 8 weeks after baseline visit assessed by PASAPQ Part II Q15 score", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percent of participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Training HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}, {"id": "OG001", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}, {"id": "OG002", "title": "No Preference", "description": "HCPs indicated no preference of device during training with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device or placebo comparator: SYMBICORT\u00ae Turbohaler using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "460"}, {"groupId": "OG001", "value": "460"}, {"groupId": "OG002", "value": "460"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "7"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "No adverse event data was collected.", "eventGroups": [{"id": "EG000", "title": "SYMBICORT Turbohaler\u00ae", "description": "Training HCPs with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device at baseline", "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}, {"id": "EG001", "title": "Budesonide/Formoterol (BF) Spiromax\u00ae", "description": "Traing HCPs with a placebo comparator: Budesonide/Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: Budesonide/Formoterol (BF) Spiromax\u00ae: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nPlacebo Comparator: SYMBICORT\u00ae Turbohaler: Training with a placebo comparator: SYMBICORT Turbohaler\u00ae device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.\n\nTraining HCPs: Training HCPS with both devices using a 6-level system to examine the number of levels required to acquire mastery of device", "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Assoc Prof Sinthia Bosnic-Anticevich", "organization": "Sydney Medical School, University of Sydney & Woolcock Institute of Medical Research", "email": "sinthia.bosnic-anticevich@sydney.edu.au", "phone": "+61 2 9114 0040"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"browseLeaves": [{"id": "M4556", "name": "Asthma", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "relevance": "LOW"}, {"id": "M304", "name": "Formoterol Fumarate", "relevance": "LOW"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}